This Biotech Startup Wants to Delay Menopause by 15 Years

Menopause begins when someone’s ovaries produce far less estrogen and progesterone than they once did. This causes said ovaries to slow the release of follicles that influence one’s ability to reproduce. Though everyone hits menopause at a bit of a different pace, Beim believes she and her firm can offset the beginning of this phase by 10 to 15 years, pushing the average onset age up to 70 years old. This would both extend a patient’s fertility and hinder the health issues that coincide with the beginning of menopause, like heart disease, bone disease, and Alzheimer’s.

“If we could buy women an extra 10 to 15 years of natural endocrine function, we’re talking about a huge boost in their vitality and their wellness at a critical stage in their life,” Beim told Fortune when Celmatix’s mission became public last year. Celmatix plans on starting clinical trials of its menopause-delaying drug in 2023. The trials will begin with women undergoing chemotherapy, which is a common cause of premature menopause.

Celmatix’s drug primarily works by mimicking anti-Mullerian hormone (AMH), which ovarian follicles naturally produce to regulate the body’s reproductive functions. Patients will be able to stop taking the drug if they wish to have a baby, just like they already do with birth control. Celmatix is also working under a grant from the Bill and Melinda Gates Foundation to experiment with new non-hormonal birth control, as hormonal options come with a slew of side effects that make most contraceptives unappealing.

Healthcare options largely impacting women have long been under-researched and under-funded for reasons we won’t go into here, but Beim sees big change on the horizon. Since 2020 Celmatix has been working with multinational pharmaceutical and life sciences company Bayer, which has sunk hundreds of millions of dollars into women’s healthcare research in recent years. An increase in awareness of women’s health issues, along with the growth of “femtech” (medical technology focused on those assigned female at birth) are also helping medical professionals take their patients’ experiences more seriously.

Continue reading

Astronomers Spot Earth-Sized Rogue Planet Wandering the Galaxy

Astronomers have identified more than 4,000 exoplanets orbiting other stars but just a few "rogue planets" wandering the galaxy without a star to call home. A new study claims to have spotted one of these worlds, and it may be a small, rocky world like Earth.

Xbox Series X Review: The Living Room Gaming PC I’ve (Mostly) Always Wanted

The Xbox Series X launches in five days, and we're clear to talk about it. I've never done a console review before, so I went into this from the perspective of what I'm used to — PC gaming. Microsoft objectively has a lot to be proud of, here.

Intel Tosses CEO Bob Swan, Appoints Pat Gelsinger to Top Job

Intel is replacing Bob Swan as CEO by inviting an old familiar face back into the fold. Pat Gelsinger, a longtime Intel veteran, will return to take over the top job.

If You Want a Mobile 10nm CPU in Your Desktop, This Might Be Your Shot

If you've ever wanted a mobile chip you could stick in an Intel desktop board, it's possible to get one. CPU support, however, is an open question.